- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04093505
Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia) (GnG)
Randomized Phase-III Study to Compare Two Schedules of Gemtuzumab Ozogamicin as Adjunct to Intensive Induction Therapy and to Compare Intensive Postremission Therapy Double Blinded With or Without Glasdegib in Older Patients With Newly Diagnosed AML
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Baden-Württemberg
-
Heidelberg, Baden-Württemberg, Germany, 69120
- University Hospital Heidelberg, Internal Medicine V
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with newly diagnosed acute myeloid leukemia according to the 2016 WHO classification
- Genetic and immunophenotypic assessment in one of the central laboratories
- No prior chemotherapy for leukemia except hydroxyurea to control hyperleukocytosis (≤ 7 days)
- Age ≥ 60 years, no upper age limit
- ECOG performance status (ECOG PS) ≤ 2. See appendix 18.1
Pregnancy and childbearing potential:
- Non-pregnant and non-nursing women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within a sensitivity of at least 25 mIU/mL within 72 hours prior to registration ("Women of childbearing potential" is defined as a sexually active mature woman who has not undergone a hysterectomy or who has had menses at any time in the preceding 24 consecutive months).
- Female patients of reproductive age must agree to avoid getting pregnant while on therapy.
- WOCBP must either commit to continued abstinence from heterosexual intercourse or begin one acceptable method of birth control (IUD, tubal ligation, or partner's vasectomy) during study and 6 months after end of study/treatment. Hormonal contraception is an inadequate method of birth control.
- Men must use a latex condom during any sexual contact with women of childbearing potential, even if they have undergone a successful vasectomy and must agree to avoid to father a child during study and 6 months after end of study/treatment
- Signed written informed consent
- Ability of patient to understand character and consequences of the clinical trial
Exclusion Criteria
- AML with PML-RARA or BCR-ABL1
- Patients with known active central nervous system leukemia (assessed clinically).
- Prior treatment with a smoothened inhibitor (SMOi) and/or hypomethylating agent for AML. (Treatment of a preceding MDS (myelodysplastic syndrome) with HMA is not an exclusion criterion.)
- Inadequate renal function: creatinine > 1.5 x upper normal serum level; estimated creatinine clearance ≤30 ml/min (calculated using the standard method for the institution).
- Inadequate liver function: ALT and AST ≥ 2.5 x ULN), total bilirubin ≥ 1.5 x ULN; Alkaline phosphatase ≥ 2.5 x ULN. Known liver cirrhosis or history of veno-occlusive disease (VOD) or history of Sinusoidal Obstruction Syndrome (SOS)
- Uncontrolled hypertension; severe obstructive or restrictive ventilation disorder
- Any one of the following ongoing or in the previous 6 months: myocardial infarction, congenital long QT syndrome, Torsades de pointes, arrhythmias (including sustained ventricular tachyarrhythmia), right or left bundle branch block and bifascicular block, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure (CHF NYHA III/IV), cerebrovascular accident, transient ischemic attack or symptomatic pulmonary embolism; as well as bradycardia defined as <50 bpms
- QTc interval >470 msec using the Fredericia correction (QTcF).
- Uncontrolled infection
- Patients known to be refractory to platelet or packed red cell transfusions as per institutional guidelines, or who are known to refuse or who are likely to refuse blood product support.
- Patients with a "currently active" second malignancy other than non-melanoma skin cancer. Patients are not considered to have a "currently active" malignancy if they have completed therapy for more than one year and are considered by their physician to be at less than 30% risk of relapse within one year.
- Severe neurologic or psychiatric disorder interfering with ability of giving informed consent
- Known or suspected active alcohol or drug abuse
- Known positivity for HIV, active HBV, HCV, or hepatitis A infection
- Evidence or history of severe non-leukemia associated bleeding diathesis or coagulopathy
- No consent for biobanking and for registration, storage and processing of the individual disease-characteristics and course as well as information of the family physician about study participation.
- Pregnancy and lactation
- History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product
- Participation in a clinical study involving an investigational drug(s) (Phases 1-4) within 4 weeks prior to study entry.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: GO147_G
GO147: Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on days 1,4 and 7 _G: Consolidation & Maintenance therapy Glasdegib 100mg on days 4 to 27 |
Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on days 1,4 and 7
Other Names:
Consolidation & Maintenance therapy Glasdegib 100mg on days 4 to 27
Other Names:
|
Placebo Comparator: GO147_P
GO147: Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on days 1,4 and 7 _P: Consolidation & Maintenance therapy Placebo 100mg on days 4 to 27 |
Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on days 1,4 and 7
Other Names:
Consolidation & Maintenance therapy Placebo 100mg on days 4 to 27
Other Names:
|
Experimental: GO1_G
GO1: Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on day 1 _G: Consolidation & Maintenance therapy Glasdegib 100mg on days 4 to 27 |
Consolidation & Maintenance therapy Glasdegib 100mg on days 4 to 27
Other Names:
Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on day 1
Other Names:
|
Placebo Comparator: GO1_P
GO1: Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on day 1 _P: Consolidation & Maintenance therapy Placebo 100mg on days 4 to 27 |
Consolidation & Maintenance therapy Placebo 100mg on days 4 to 27
Other Names:
Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on day 1
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MRD-negativity
Time Frame: Collected during the first MRD-analysis after the first induction therapy cycle (after 4 weeks)
|
Minimal Residual Disease negativity (MRD-negativity) after induction therapy measured by flow cytometry.
|
Collected during the first MRD-analysis after the first induction therapy cycle (after 4 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
EFS
Time Frame: Collected after 2 years follow-up time
|
Event-free survival
|
Collected after 2 years follow-up time
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCT-2017-0537
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
Massachusetts General HospitalExelixisCompletedRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
Advesya SASNot yet recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryFrance, Sweden, Spain, Germany
-
Keystone Nano, IncMilton S. Hershey Medical Center; University of VirginiaNot yet recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, RefractoryUnited States
-
National Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Adult Acute Monoblastic Leukemia | Adult Acute Monocytic Leukemia | Adult Acute Myeloid Leukemia With Maturation | Adult Acute Myeloid Leukemia Without Maturation | Adult Acute Myelomonocytic Leukemia | Alkylating Agent-Related Acute Myeloid... and other conditionsUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Oryzon Genomics S.A.RecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryUnited States
-
University Hospital, AntwerpRecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryBelgium
-
Medical College of WisconsinRecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryUnited States
-
Stanford UniversityCelgene CorporationCompletedAcute Myeloid Leukemia (AML) | Adult Acute Myeloblastic LeukemiaUnited States
Clinical Trials on Gemtuzumab Ozogamicin 147
-
University of AarhusCompleted
-
PfizerCompletedLeukemiaUnited States
-
University Hospital Carl Gustav CarusUnknownAcute Myeloid Leukemia | Allogeneic TransplantationGermany
-
PfizerCompletedLeukemia, Myeloid, AcuteUnited States
-
PfizerCompleted
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)UnknownMyelodysplastic SyndromesUnited States
-
European Organisation for Research and Treatment...Gruppo Italiano Malattie EMatologiche dell'AdultoUnknownLeukemiaBelgium, Italy, Netherlands
-
Merck Sharp & Dohme LLCTerminatedLeukemia, Myeloid, Acute | Lymphoblastic Leukemia, Acute
-
Medical College of WisconsinCompletedRelapsed Adult AMLUnited States
-
Versailles HospitalUnknown